Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             385 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Accelerated clearance systems Sharma, S.K.
 1996
 82-83 3 p. 315-324
10 p.
 artikel
2 (A) Cell biology of epithelia Mackay, Martin
 1991
 82-83 3 p. 313-338
26 p.
 artikel
3 A critical view on lactose-based drug formulation and device studies for dry powder inhalation: Which are relevant and what interactions to expect? de Boer, A.H.
 2012
 82-83 3 p. 257-274
18 p.
 artikel
4 Adeno-associated virus (AAV) vectors for gene transfer Xiao, Xiao
 1993
 82-83 3 p. 201-215
15 p.
 artikel
5 Adenoviral vectors for gene transfer Trapnell, Bruce C.
 1993
 82-83 3 p. 185-199
15 p.
 artikel
6 Adenovirus-mediated gene transfer to liver Wilson, James M.
 1995
 82-83 3 p. 303-307
5 p.
 artikel
7 Adjuvant activity of incomplete Freund's adjuvant Chang, Jennie C.C
 1998
 82-83 3 p. 173-186
14 p.
 artikel
8 Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption Ezra, Aviva
 2000
 82-83 3 p. 175-195
21 p.
 artikel
9 Adoptive immunotherapy of HIV and CMV Gilbert, M.J.
 1995
 82-83 3 p. 359-362
4 p.
 artikel
10 Adoptive transfer of immunity to hepatitis B: development of the concept and evolution of the research project for targeted immunotherapy against hepatic cells which express a viral antigen Shouval, Daniel
 1995
 82-83 3 p. 317-320
4 p.
 artikel
11 Advanced drug delivery reviews: enzyme prodrug therapy Sherwood, Roger F.
 1996
 82-83 3 p. 269-288
20 p.
 artikel
12 Advances in recombinant retroviruses for gene delivery Morgan, Jeffrey R.
 1993
 82-83 3 p. 143-158
16 p.
 artikel
13 Alkylating agent prodrugs for ADEPT Burke, P.J.
 1996
 82-83 3 p. 331-340
10 p.
 artikel
14 Aluminum compounds as vaccine adjuvants Gupta, Rajesh K
 1998
 82-83 3 p. 155-172
18 p.
 artikel
15 A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: A strategy for overcoming the PEG dilemma Hatakeyama, Hiroto
 2011
 82-83 3 p. 152-160
9 p.
 artikel
16 An integrated pharmacokinetic–pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease Danhof, M
 1998
 82-83 3 p. 253-263
11 p.
 artikel
17 Announcement 1990
 82-83 3 p. iii-
1 p.
 artikel
18 A novel non-viral gene transfer system, polycation liposomes Oku, Naoto
 2001
 82-83 3 p. 209-218
10 p.
 artikel
19 Antibody-directed liposomes as drug-delivery vehicles Wright, Stephen
 1989
 82-83 3 p. 343-389
47 p.
 artikel
20 Antibody mediated therapy Baxter, Laurence T.
 1995
 82-83 3 p. 255-256
2 p.
 artikel
21 Anti-idiotype antibodies and immunization against infectious diseases Schick, Michael R.
 1988
 82-83 3 p. 343-357
15 p.
 artikel
22 Anti-idiotypes and cancer therapy Lee, Victor K.
 1988
 82-83 3 p. 271-296
26 p.
 artikel
23 Antisense oligonucleotides: gene regulation and chemotherapy of AIDS Agrawal, Sudhir
 1991
 82-83 3 p. 251-270
20 p.
 artikel
24 Antiviral therapy of hepatitis B virus infection: Blocking viral gene expression Blum, Hubert E.
 1995
 82-83 3 p. 321-331
11 p.
 artikel
25 Application of membrane-active peptides for nonviral gene delivery Wagner, Ernst
 1999
 82-83 3 p. 279-289
11 p.
 artikel
26 Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation Okamoto, Hirokazu
 2008
 82-83 3 p. 433-446
14 p.
 artikel
27 Applications of process analytical technology to crystallization processes Yu, Lawrence X
 2004
 82-83 3 p. 349-369
21 p.
 artikel
28 Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering Davies, Owen R.
 2008
 82-83 3 p. 373-387
15 p.
 artikel
29 Approaches for generating recombinant adenovirus vectors Mizuguchi, Hiroyuki
 2001
 82-83 3 p. 165-176
12 p.
 artikel
30 Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides Mutwiri, George
 2009
 82-83 3 p. 226-232
7 p.
 artikel
31 Aquaculture pharmaceuticals and biologicals: current perspectives and future possibilities Shao, Zezhi J
 2001
 82-83 3 p. 229-243
15 p.
 artikel
32 A summary of monoclonal antibody-enzyme/prodrug Senter, Peter D.
 1996
 82-83 3 p. 341-349
9 p.
 artikel
33 A timely re-examination of drug polymorphism in pharmaceutical development and regulation Grant, David J.W.
 2004
 82-83 3 p. 237-239
3 p.
 artikel
34 Author index 1988
 82-83 3 p. 273-
1 p.
 artikel
35 Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications Fadeel, Bengt
 2010
 82-83 3 p. 362-374
13 p.
 artikel
36 Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery Alpar, H. Oya
 2005
 82-83 3 p. 411-430
20 p.
 artikel
37 Biodegradable nanoparticles for drug and gene delivery to cells and tissue Panyam, Jayanth
 2003
 82-83 3 p. 329-347
19 p.
 artikel
38 Biodegradable particle formation for drug and gene delivery using supercritical fluid and dense gas Mishima, Kenji
 2008
 82-83 3 p. 411-432
22 p.
 artikel
39 Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens Jiang, Wenlei
 2005
 82-83 3 p. 391-410
20 p.
 artikel
40 Biodistribution studies Begent, R.H.J.
 1996
 82-83 3 p. 325-329
5 p.
 artikel
41 Bioerodible polymers for delivery of macromolecules Smith, Kelly L.
 1990
 82-83 3 p. 343-357
15 p.
 artikel
42 Biological barriers to cellular delivery of lipid-based DNA carriers Bally, Marcel B
 1999
 82-83 3 p. 291-315
25 p.
 artikel
43 Biomedical micro- and nano-technology 2003
 82-83 3 p. 311-313
3 p.
 artikel
44 Blood substitutes Winslow, Robert M
 2000
 82-83 3 p. 131-142
12 p.
 artikel
45 (B) Mechanisms of peptide and protein absorption Burton, Philip S.
 1991
 82-83 3 p. 365-385
21 p.
 artikel
46 (B) Mechanisms of peptide and protein absorption Nellans, Hugh N.
 1991
 82-83 3 p. 339-364
26 p.
 artikel
47 Bone marrow purging: an appraisal of immunological and non-immunological methods Treleaven, J.G.
 1988
 82-83 3 p. 253-269
17 p.
 artikel
48 Bovine mastitis and intramammary drug delivery: review and perspectives Gruet, P
 2001
 82-83 3 p. 245-259
15 p.
 artikel
49 Calcium-level responsive controlled drug delivery from implant dosage forms to treat osteoporosis in an animal model Otsuka, Makoto
 2000
 82-83 3 p. 249-258
10 p.
 artikel
50 ‘Carbohydrate handles’ as natural resources in drug delivery Palomino, Eduardo
 1994
 82-83 3 p. 311-323
13 p.
 artikel
51 Carbohydrate-mediated liposomal targeting and drug delivery Jones, Malcolm N.
 1994
 82-83 3 p. 215-249
35 p.
 artikel
52 Caveolae and intracellular trafficking of cholesterol Fielding, Christopher J.
 2001
 82-83 3 p. 251-264
14 p.
 artikel
53 Caveolae and the caveolins in human disease Campbell, Lee
 2001
 82-83 3 p. 325-335
11 p.
 artikel
54 Caveolae as potential macromolecule trafficking compartments within alveolar epithelium Gumbleton, Mark
 2001
 82-83 3 p. 281-300
20 p.
 artikel
55 Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo Schnitzer, Jan E
 2001
 82-83 3 p. 265-280
16 p.
 artikel
56 Caveolae in the uptake and targeting of infectious agents and secreted toxins Norkin, Leonard C
 2001
 82-83 3 p. 301-315
15 p.
 artikel
57 Caveolae-mediated membrane transport 2001
 82-83 3 p. 217-221
5 p.
 artikel
58 Cell biology of caveolae and caveolin Couet, Jacques
 2001
 82-83 3 p. 223-235
13 p.
 artikel
59 Cell-specific delivery of genes with glycosylated carriers Hashida, Mitsuru
 2001
 82-83 3 p. 187-196
10 p.
 artikel
60 Cellular uptake of antisense oligodeoxynucleotides Jaroszewski, Jerzy W.
 1991
 82-83 3 p. 235-250
16 p.
 artikel
61 Cervical mucus Katz, David F.
 1993
 82-83 3 p. 385-401
17 p.
 artikel
62 Clinical application of phospholipid liposomes containing macrophage activators for therapy of cancer metastasis Fidler, Isaiah J.
 1994
 82-83 3 p. 325-340
16 p.
 artikel
63 Clinical experience and applications of drug-eluting stents in the noncoronary vasculature, bile duct and esophagus Machan, Lindsay
 2006
 82-83 3 p. 447-462
16 p.
 artikel
64 Clinical trials in gene therapy Freeman, Scott M.
 1993
 82-83 3 p. 169-183
15 p.
 artikel
65 Comparative modelling of cytochromes P450 Kirton, Stewart B
 2002
 82-83 3 p. 385-406
22 p.
 artikel
66 Computational approaches to the prediction of the blood–brain distribution Norinder, Ulf
 2002
 82-83 3 p. 291-313
23 p.
 artikel
67 Computational methods for the prediction of ADME and Toxicity 2002
 82-83 3 p. 253-254
2 p.
 artikel
68 Computer systems for the prediction of toxicity: an update Greene, Nigel
 2002
 82-83 3 p. 417-431
15 p.
 artikel
69 Computer systems for the prediction of xenobiotic metabolism Langowski, Jan
 2002
 82-83 3 p. 407-415
9 p.
 artikel
70 Concepts in the delivery of monoclonal antibodies in the targeting of human carcinomas Schlom, Jeffrey
 1988
 82-83 3 p. 229-251
23 p.
 artikel
71 Conceptual and commercially available intravaginal veterinary drug delivery systems Rathbone, Michael J
 1997
 82-83 3 p. 363-392
30 p.
 artikel
72 Confocal and probe microscopy to study gene transfection mediated by cationic liposomes with a cationic cholesterol derivative Nakanishi, Mamoru
 2001
 82-83 3 p. 197-207
11 p.
 artikel
73 Contents of volume 11 1993
 82-83 3 p. 433-
1 p.
 artikel
74 Contents of volume 12 1993
 82-83 3 p. 221-
1 p.
 artikel
75 Contents of volume 6 1991
 82-83 3 p. 322-
1 p.
 artikel
76 Contents of volume 7 1991
 82-83 3 p. 390-
1 p.
 artikel
77 Contents of volume 13 1994
 82-83 3 p. 345-
1 p.
 artikel
78 Contents of volume 2 1988
 82-83 3 p. 372-
1 p.
 artikel
79 Contents of volume 4 1990
 82-83 3 p. 429-
1 p.
 artikel
80 Contents of volume 3 1989
 82-83 3 p. 425-
1 p.
 artikel
81 Contents of volume 1 1988
 82-83 3 p. 275-
1 p.
 artikel
82 Controlling the higher-order structure of giant DNA molecules Yoshikawa, Kenichi
 2001
 82-83 3 p. 235-244
10 p.
 artikel
83 Control of pharmacokinetic profiles of drug—macromolecule conjugates Takakura, Yoshinobu
 1996
 82-83 3 p. 377-399
23 p.
 artikel
84 Corrigendum to: “Implantable, polymeric systems for modulated drug delivery” Sershen, S.
 2003
 82-83 3 p. 439-
1 p.
 artikel
85 CpG oligodeoxynucleotide-based therapy of lymphoid malignancies Weiner, George J.
 2009
 82-83 3 p. 263-267
5 p.
 artikel
86 CpG oligonucleotide as an adjuvant for the treatment of prostate cancer Lubaroff, David M.
 2009
 82-83 3 p. 268-274
7 p.
 artikel
87 CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases Klinman, Dennis M.
 2009
 82-83 3 p. 248-255
8 p.
 artikel
88 CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies Salem, Aliasger K.
 2009
 82-83 3 p. 193-194
2 p.
 artikel
89 CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma Miles, Suzanne A.
 2009
 82-83 3 p. 275-282
8 p.
 artikel
90 Cumulative article index 1990
 82-83 3 p. 301-304
4 p.
 artikel
91 Cumulative author index 1991
 82-83 3 p. 309-313
5 p.
 artikel
92 Cumulative author index 1993
 82-83 3 p. 425-432
8 p.
 artikel
93 Cumulative author index 1988
 82-83 3 p. 368-369
2 p.
 artikel
94 Cumulative author index 1989
 82-83 3 p. 419-421
3 p.
 artikel
95 Cumulative author index 1990
 82-83 3 p. 421-424
4 p.
 artikel
96 Cumulative key word index 1991
 82-83 3 p. 314-320
7 p.
 artikel
97 Cumulative key word index 1988
 82-83 3 p. 370-371
2 p.
 artikel
98 Cumulative key word index 1990
 82-83 3 p. 425-428
4 p.
 artikel
99 Cumulative key word index 1989
 82-83 3 p. 422-424
3 p.
 artikel
100 Current aspects in pharmacology of modified hemoglobins Palaparthy, Rameshraja
 2000
 82-83 3 p. 185-198
14 p.
 artikel
101 Current perspectives and challenges in the use of monoclonal antibodies as imaging and therapeutic agents Blumenthal, Rosalyn D.
 1990
 82-83 3 p. 279-318
40 p.
 artikel
102 Current status of artificial oxygen carriers Spahn, Donat R
 2000
 82-83 3 p. 143-151
9 p.
 artikel
103 Cytosolic drug delivery using pH- and light-sensitive liposomes Gerasimov, Oleg V.
 1999
 82-83 3 p. 317-338
22 p.
 artikel
104 Design and evaluation of IR sensors for pharmaceutical testing Baulsir, Cindy F.
 1996
 82-83 3 p. 191-203
13 p.
 artikel
105 Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging Veiseh, Omid
 2010
 82-83 3 p. 284-304
21 p.
 artikel
106 Design and gene delivery activity of modified polyethylenimines Kircheis, Ralf
 2001
 82-83 3 p. 341-358
18 p.
 artikel
107 Design of a drug delivery system for targeting based on pharmacokinetic consideration Suzuki, Hiroshi
 1996
 82-83 3 p. 335-357
23 p.
 artikel
108 Design of polymer materials enhancing nucleotide hybridization for anti-gene technology Maruyama, Atsushi
 2001
 82-83 3 p. 227-233
7 p.
 artikel
109 Design strategies to improve soluble macromolecular delivery constructs Christie, R.J
 2003
 82-83 3 p. 421-437
17 p.
 artikel
110 Development and application of PROVAX™ adjuvant formulation for subunit cancer vaccines Hariharan, Kandasamy
 1998
 82-83 3 p. 187-197
11 p.
 artikel
111 Development of adjuvant-active nonionic block copolymers Newman, Mark J
 1998
 82-83 3 p. 199-223
25 p.
 artikel
112 DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells Jilek, Samantha
 2005
 82-83 3 p. 377-390
14 p.
 artikel
113 Drug delivery applications of supercritical fluid technology Kawashima, Yoshiaki
 2008
 82-83 3 p. 297-298
2 p.
 artikel
114 Drug delivery through the blood-brain barrier Tamai, Ikumi
 1996
 82-83 3 p. 401-424
24 p.
 artikel
115 Drug delivery using buccal-adhesive systems Smart, John D.
 1993
 82-83 3 p. 253-270
18 p.
 artikel
116 Drug-eluting stents: A multidisciplinary success story Burt, Helen M.
 2006
 82-83 3 p. 350-357
8 p.
 artikel
117 Drug-eluting stents: an innovative multidisciplinary drug delivery platform Burt, Helen M.
 2006
 82-83 3 p. 345-346
2 p.
 artikel
118 Drug-eluting stents: Beyond the hyperbole Hunter, William L.
 2006
 82-83 3 p. 347-349
3 p.
 artikel
119 Drug-eluting stents: Factors governing local pharmacokinetics Yang, Chiming
 2006
 82-83 3 p. 402-411
10 p.
 artikel
120 Drug–lactose binding aspects in adhesive mixtures: Controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces Zhou, Qi (Tony)
 2012
 82-83 3 p. 275-284
10 p.
 artikel
121 Drug-oligonucleotide conjugates Byrn, S.R.
 1991
 82-83 3 p. 287-308
22 p.
 artikel
122 Drug polymorphism and dosage form design: a practical perspective Singhal, Dharmendra
 2004
 82-83 3 p. 335-347
13 p.
 artikel
123 Editorial 1998
 82-83 3 p. 183-184
2 p.
 artikel
124 Editorial 1998
 82-83 3 p. 183-184
2 p.
 artikel
125 Editorial Board 2009
 82-83 3 p. ii-
1 p.
 artikel
126 Editorial Board 2010
 82-83 3 p. ii-
1 p.
 artikel
127 Editorial Board 2013
 82-83 3 p. ii-
1 p.
 artikel
128 Editorial Board 2003
 82-83 3 p. ii-
1 p.
 artikel
129 Editorial Board 2006
 82-83 3 p. ii-
1 p.
 artikel
130 Editorial Board 2004
 82-83 3 p. ii-
1 p.
 artikel
131 Editorial Board 2008
 82-83 3 p. ii-
1 p.
 artikel
132 Editorial Board 2005
 82-83 3 p. ii-
1 p.
 artikel
133 Editorial Board 2012
 82-83 3 p. ii-
1 p.
 artikel
134 Editorial Board 2011
 82-83 3 p. ii-
1 p.
 artikel
135 Endocytosis and transcytosis Okamoto, Curtis T
 1998
 82-83 3 p. 215-228
14 p.
 artikel
136 Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles Malyala, Padma
 2009
 82-83 3 p. 218-225
8 p.
 artikel
137 Environment-sensitive hydrogels for drug delivery Qiu, Yong
 2001
 82-83 3 p. 321-339
19 p.
 artikel
138 Enzyme-activated targeting of liposomes Meers, Paul
 2001
 82-83 3 p. 265-272
8 p.
 artikel
139 EPD, a novel technology for drug delivery Zhao, Xi
 1995
 82-83 3 p. 257-262
6 p.
 artikel
140 EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy Maeda, Hiroshi
 2011
 82-83 3 p. 129-130
2 p.
 artikel
141 Exosomal tumor-suppressive microRNAs as novel cancer therapy Kosaka, Nobuyoshi
 2013
 82-83 3 p. 376-382
7 p.
 artikel
142 Exosomes are endogenous nanoparticles that can deliver biological information between cells Sun, Dongmei
 2013
 82-83 3 p. 342-347
6 p.
 artikel
143 Exosomes as nano-theranostic delivery platforms for gene therapy Tan, Aaron
 2013
 82-83 3 p. 357-367
11 p.
 artikel
144 Exosomes as nucleic acid nanocarriers van den Boorn, Jasper G.
 2013
 82-83 3 p. 331-335
5 p.
 artikel
145 Exosomes for targeted siRNA delivery across biological barriers EL Andaloussi, Samir
 2013
 82-83 3 p. 391-397
7 p.
 artikel
146 Exploiting receptor biology for oral vaccination with biodegradable particulates Foster, Neil
 2005
 82-83 3 p. 431-450
20 p.
 artikel
147 Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer Patra, Chitta Ranjan
 2010
 82-83 3 p. 346-361
16 p.
 artikel
148 Feasibility of topical liposome drugs produced on an industrial scale Naeff, Rainer
 1996
 82-83 3 p. 343-347
5 p.
 artikel
149 First clinical experience with ADEPT Bagshawe, K.D.
 1996
 82-83 3 p. 365-367
3 p.
 artikel
150 Formulation aspects of biodegradable polymeric microspheres for antigen delivery Tamber, Harjit
 2005
 82-83 3 p. 357-376
20 p.
 artikel
151 Forthcoming articles 1994
 82-83 3 p. 341-
1 p.
 artikel
152 Forthcoming articles 1991
 82-83 3 p. 387-
1 p.
 artikel
153 Forthcoming articles 1993
 82-83 3 p. 217-218
2 p.
 artikel
154 Forthcoming articles 1993
 82-83 3 p. 419-420
2 p.
 artikel
155 Forthcoming event 1991
 82-83 3 p. 389-
1 p.
 artikel
156 Forthcoming events 1993
 82-83 3 p. 421-423
3 p.
 artikel
157 Forthcoming events 1993
 82-83 3 p. 219-220
2 p.
 artikel
158 Forthcoming events 1994
 82-83 3 p. 343-344
2 p.
 artikel
159 Forthcoming events 1991
 82-83 3 p. 321-
1 p.
 artikel
160 Forthcoming eventsctive and progressive in lymphoid tissue during the clinically latent stage of disease 1995
 82-83 3 p. 373-374
2 p.
 artikel
161 Future challenges for drug delivery research 1 This paper is the summary of the author's key-note lecture at the Annual CRS Congress, Stockholm, June 1997. 1 Breimer, D.D
 1998
 82-83 3 p. 265-268
4 p.
 artikel
162 Gene delivery systems: viral vs. non-viral vectors Kataoka, Kazunori
 2001
 82-83 3 p. 151-
1 p.
 artikel
163 Gene-directed enzyme prodrug therapy (GDEPT): choice of prodrugs Springer, C.J.
 1996
 82-83 3 p. 351-364
14 p.
 artikel
164 General principles of pharmaceutical solid polymorphism Rodrı́guez-Spong, Barbara
 2004
 82-83 3 p. 241-274
34 p.
 artikel
165 Generating and loading of liposomal systems for drug-delivery applications Cullis, P.R.
 1989
 82-83 3 p. 267-282
16 p.
 artikel
166 Gene therapy for metabolic disorders Bowles, Neil
 1995
 82-83 3 p. 293-302
10 p.
 artikel
167 Gene therapy of the gut: introduction of the APC tumor-suppressor gene for cancer prevention or treatment Westbrook, Carol A.
 1995
 82-83 3 p. 349-355
7 p.
 artikel
168 Genetic manipulation in mammalian cells using an RNA/DNA chimeric oligonucleotide Kmiec, Eric B.
 1995
 82-83 3 p. 333-340
8 p.
 artikel
169 Gene transfer into the intestinal epithelium Henning, Susan J.
 1995
 82-83 3 p. 341-347
7 p.
 artikel
170 Guide to Authors 2001
 82-83 3 p. 337-339
3 p.
 artikel
171 Guide to Authors 2004
 82-83 3 p. 415-418
4 p.
 artikel
172 Guide to Authors 2005
 82-83 3 p. 483-486
4 p.
 artikel
173 Hepatic gene expression after direct DNA injection Hickman, M.Anne
 1995
 82-83 3 p. 265-271
7 p.
 artikel
174 High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids Morissette, Sherry L.
 2004
 82-83 3 p. 275-300
26 p.
 artikel
175 Human genetic disease and the medical need for somatic gene therapy Moseley, A.B.
 1993
 82-83 3 p. 131-142
12 p.
 artikel
176 Human gene transfer trials Wivel, Nelson
 1995
 82-83 3 p. 211-212
2 p.
 artikel
177 Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models Suetsugu, Atsushi
 2013
 82-83 3 p. 383-390
8 p.
 artikel
178 Immobilised enzymes as drugs Torchilin, V.P.
 1988
 82-83 3 p. 270-
1 p.
 artikel
179 Immune response in ADEPT Sharma, S.K.
 1996
 82-83 3 p. 369-376
8 p.
 artikel
180 Immunity in response to particulate antigen-delivery systems Storni, Tazio
 2005
 82-83 3 p. 333-355
23 p.
 artikel
181 Immunoliposomes in vivo: state of the art Peeters, Pierre A.M.
 1988
 82-83 3 p. 249-266
18 p.
 artikel
182 Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists Vollmer, Jörg
 2009
 82-83 3 p. 195-204
10 p.
 artikel
183 Immunotoxins: properties, applications and current limitations Lord, J.Michael
 1988
 82-83 3 p. 297-318
22 p.
 artikel
184 Impact of pharmacodynamic variability on drug delivery1 Levy, Gerhard
 1998
 82-83 3 p. 201-206
6 p.
 artikel
185 Impact of solid state properties on developability assessment of drug candidates Huang, Lian-Feng
 2004
 82-83 3 p. 321-334
14 p.
 artikel
186 Importance of pharmacokinetic considerations in the development of drug delivery systems Sugiyama, Yuichi
 1996
 82-83 3 p. 333-334
2 p.
 artikel
187 Importance of receptor-mediated endocytosis in peptide delivery and targeting: kinetic aspects Sato, Hitoshi
 1996
 82-83 3 p. 445-467
23 p.
 artikel
188 Inclusion and release of proteins from polysaccharide-based polyion complexes Dumitriu, Severian
 1998
 82-83 3 p. 223-246
24 p.
 artikel
189 Inhibition of HIV-1 with intracellular immunization with RNA decoys Smith, Clay
 1995
 82-83 3 p. 369-371
3 p.
 artikel
190 Injectable retroviral particles for human gene therapy Squinto, Stephen P.
 1995
 82-83 3 p. 213-226
14 p.
 artikel
191 Innovative strategies for co-delivering antigens and CpG oligonucleotides Krishnamachari, Yogita
 2009
 82-83 3 p. 205-217
13 p.
 artikel
192 Instructions to authors 2003
 82-83 3 p. 441-443
3 p.
 artikel
193 Interaction of liposomes with human skin: the role of the stratum corneum Schaller, M.
 1996
 82-83 3 p. 303-309
7 p.
 artikel
194 Intestinal translocation of particulates — implications for drug and antigen delivery O'Hagan, D.T.
 1990
 82-83 3 p. 265-285
21 p.
 artikel
195 Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects Maruyama, Kazuo
 2011
 82-83 3 p. 161-169
9 p.
 artikel
196 Intracellular trafficking and transgene expression of viral and non-viral gene vectors Kamiya, H
 2001
 82-83 3 p. 153-164
12 p.
 artikel
197 Intraruminal devices Cardinal, John R
 1997
 82-83 3 p. 303-322
20 p.
 artikel
198 Introduction Bagshawe, Kenneth D.
 1996
 82-83 3 p. 265-268
4 p.
 artikel
199 Iontophoresis: an alternative to the use of carriers in cutaneous drug delivery Singh, Parminder
 1996
 82-83 3 p. 379-394
16 p.
 artikel
200 ISCOMATRIX® adjuvant for antigen delivery Pearse, Martin J.
 2005
 82-83 3 p. 465-474
10 p.
 artikel
201 ISCOMs and other saponin based adjuvants Barr, I.G
 1998
 82-83 3 p. 247-271
25 p.
 artikel
202 Key word index 1988
 82-83 3 p. 274-
1 p.
 artikel
203 Lab-on-a-chip for drug development Weigl, Bernhard H.
 2003
 82-83 3 p. 349-377
29 p.
 artikel
204 Lactose as a carrier for inhalation products: breathing new life into an old carrier Marriott, Chris
 2012
 82-83 3 p. 217-219
3 p.
 artikel
205 Lactose characteristics and the generation of the aerosol Pilcer, Gabrielle
 2012
 82-83 3 p. 233-256
24 p.
 artikel
206 Ligand-targeted liposomes Forssen, Eric
 1998
 82-83 3 p. 249-271
23 p.
 artikel
207 Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy Wilson, Kaley D.
 2009
 82-83 3 p. 233-242
10 p.
 artikel
208 Lipid vesicles and membrane fusion Cevc, Gregor
 1999
 82-83 3 p. 207-232
26 p.
 artikel
209 Liposomal targeting and drug delivery: kinetic consideration Harashima, H.
 1996
 82-83 3 p. 425-444
20 p.
 artikel
210 Liposomes as a topical drug delivery system Egbaria, K.
 1990
 82-83 3 p. 287-300
14 p.
 artikel
211 Liposomes as carriers for anti-inflammatory agents Axelsson, Bengt
 1989
 82-83 3 p. 391-404
14 p.
 artikel
212 Liposomes as carriers for polypeptides Weiner, Alan L.
 1989
 82-83 3 p. 307-341
35 p.
 artikel
213 Liposomes as drug carriers for polyene antibiotics Mehta, Reeta Taneja
 1989
 82-83 3 p. 283-306
24 p.
 artikel
214 Liposomes in cancer therapy Daoud, Sayed S.
 1989
 82-83 3 p. 405-418
14 p.
 artikel
215 Liver-directed gene delivery Wu, George Y.
 1993
 82-83 3 p. 159-167
9 p.
 artikel
216 Macromolecular absorption in the gastrointestinal tract Gonnella, Patricia A.
 1988
 82-83 3 p. 235-248
14 p.
 artikel
217 Mechanisms of controlled drug release from drug-eluting stents Acharya, Ghanashyam
 2006
 82-83 3 p. 387-401
15 p.
 artikel
218 Membrane destabilization for improved cystolic delivery Storm, G
 1999
 82-83 3 p. 195-
1 p.
 artikel
219 Membrane fusion Zimmerberg , Joshua
 1999
 82-83 3 p. 197-205
9 p.
 artikel
220 Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery Yeo, Ronne Wee Yeh
 2013
 82-83 3 p. 336-341
6 p.
 artikel
221 Micro- and nanobiotechnology for biosensing cellular responses Haruyama, Tetsuya
 2003
 82-83 3 p. 393-401
9 p.
 artikel
222 Microchip-based chemical and biochemical analysis systems Sato, Kiichi
 2003
 82-83 3 p. 379-391
13 p.
 artikel
223 Microfabricated drug delivery systems: from particles to pores Tao, Sarah L
 2003
 82-83 3 p. 315-328
14 p.
 artikel
224 Micronization processes with supercritical fluids: Fundamentals and mechanisms Martín, A.
 2008
 82-83 3 p. 339-350
12 p.
 artikel
225 Microvascular permeability to macromolecules and its dynamic modulation Joyner, William L.
 1990
 82-83 3 p. 319-342
24 p.
 artikel
226 Modeling of active transport systems Zhang, Eric Y
 2002
 82-83 3 p. 329-354
26 p.
 artikel
227 Modification of tight junction function by protein kinase C isoforms Clarke, Hilary
 2000
 82-83 3 p. 283-301
19 p.
 artikel
228 Modified natural nanoparticles as contrast agents for medical imaging Cormode, David P.
 2010
 82-83 3 p. 329-338
10 p.
 artikel
229 Modulation of epithelial and endothelial paracellular permeability by leukocytes Edens, Heather A
 2000
 82-83 3 p. 315-328
14 p.
 artikel
230 Modulation of tight junctional permeability Madara, James L
 2000
 82-83 3 p. 251-253
3 p.
 artikel
231 Modulation of tight junction function by G protein-coupled events Hopkins, Ann M
 2000
 82-83 3 p. 329-340
12 p.
 artikel
232 Modulation of tight junction structure and function by cytokines Walsh, Shaun V
 2000
 82-83 3 p. 303-313
11 p.
 artikel
233 Molecular motors and their role in membrane traffic Hamm-Alvarez, Sarah F
 1998
 82-83 3 p. 229-242
14 p.
 artikel
234 Mucociliary clearance and drug delivery via the respiratory tract Lansley, Alison Batts
 1993
 82-83 3 p. 299-327
29 p.
 artikel
235 Mucus on the epidermis of fish and its influence on drug delivery Shephard, Kerry L.
 1993
 82-83 3 p. 403-417
15 p.
 artikel
236 Nanoparticles as microcarriers for anticancer drugs Couvreur, P.
 1990
 82-83 3 p. 209-230
22 p.
 artikel
237 Nanoparticles for detection and diagnosis Agasti, Sarit S.
 2010
 82-83 3 p. 316-328
13 p.
 artikel
238 Nanoparticles synthesis using supercritical fluid technology – towards biomedical applications Byrappa, K.
 2008
 82-83 3 p. 299-327
29 p.
 artikel
239 Nanoporous inorganic membranes or coatings for sustained drug delivery in implantable devices Gultepe, Evin
 2010
 82-83 3 p. 305-315
11 p.
 artikel
240 Native and modified lipoproteins as drug delivery systems Bijsterbosch, Martin K.
 1990
 82-83 3 p. 231-251
21 p.
 artikel
241 Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems Friede, M.
 2005
 82-83 3 p. 325-331
7 p.
 artikel
242 Novel vectors for gene therapy Strayer, David S.
 1995
 82-83 3 p. 235-238
4 p.
 artikel
243 Ocular drug delivery in veterinary medicine Baeyens, Vincent
 1997
 82-83 3 p. 335-361
27 p.
 artikel
244 Opportunities and challenges in the design of implantable biodegradable polymeric systems for the delivery of antimicrobial agents and vaccines Wise, Donald L.
 1988
 82-83 3 p. 269-
1 p.
 artikel
245 Opportunities and obstacles in veterinary dental drug delivery Cleland Jr, W.Paul
 2001
 82-83 3 p. 261-275
15 p.
 artikel
246 Opportunities with phage technology and antibody engineering of fusion proteins Chester, Kerry A.
 1996
 82-83 3 p. 303-313
11 p.
 artikel
247 Optical nanosensors — towards the development of intracellular monitoring Uttamchandani, Deepak
 1996
 82-83 3 p. 239-247
9 p.
 artikel
248 Optimal tumour targeting by antibodies: kinetic consideration Rouse, M.K.
 1996
 82-83 3 p. 469-484
16 p.
 artikel
249 Oral delivery of salmon calcitonin Lee, Yong-Hee
 2000
 82-83 3 p. 225-238
14 p.
 artikel
250 Parenteral emulsions for drug delivery Collins-Gold, L.C.
 1990
 82-83 3 p. 189-208
20 p.
 artikel
251 Particle design of poorly water-soluble drug substances using supercritical fluid technologies Yasuji, Takehiko
 2008
 82-83 3 p. 388-398
11 p.
 artikel
252 Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides Felgner, Philip L.
 1990
 82-83 3 p. 163-187
25 p.
 artikel
253 Particulate systems for drug delivery to the lung McCalden, Thomas A.
 1990
 82-83 3 p. 253-263
11 p.
 artikel
254 Pathogenesis of osteoporosis and challenges for drug delivery Mundy, Gregory R
 2000
 82-83 3 p. 165-173
9 p.
 artikel
255 PEGylated nanoparticles for biological and pharmaceutical applications Otsuka, Hidenori
 2003
 82-83 3 p. 403-419
17 p.
 artikel
256 Pharmaceutical and biomedical applications of fiber optic biosensors based on infra red technology Kerslake, E.D.S.
 1996
 82-83 3 p. 205-213
9 p.
 artikel
257 Pharmaceutical solid polymorphism in drug development and regulation Raw, Andre S.
 2004
 82-83 3 p. 235-236
2 p.
 artikel
258 Pharmacodynamic aspects of drug administration. Tolerance development Paalzow, Lennart K.
 1998
 82-83 3 p. 235-240
6 p.
 artikel
259 Pharmacodynamic aspects of peptide administration biological response modifiers Talmadge, James E
 1998
 82-83 3 p. 241-252
12 p.
 artikel
260 Pharmacodynamic aspects of sustained release preparations Hoffman, Amnon
 1998
 82-83 3 p. 185-199
15 p.
 artikel
261 Pharmacodynamics of variable patient compliance: implications for pharmaceutical value Urquhart, John
 1998
 82-83 3 p. 207-219
13 p.
 artikel
262 Pharmacokinetics and protein therapeutics Gloff, Carol A.
 1990
 82-83 3 p. 359-386
28 p.
 artikel
263 Pharmacophore modeling of cytochromes P450 de Groot, Marcel J.
 2002
 82-83 3 p. 367-383
17 p.
 artikel
264 Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development Kunisawa, Jun
 2001
 82-83 3 p. 177-186
10 p.
 artikel
265 Phase transformation considerations during process development and manufacture of solid oral dosage forms Zhang, Geoff G.Z
 2004
 82-83 3 p. 371-390
20 p.
 artikel
266 Phenotype and regulation of hepatic progenitor cells versus mature liver cells Brill, Shlomo
 1995
 82-83 3 p. 273-277
5 p.
 artikel
267 Phototriggering of liposomal drug delivery systems Shum, Pochi
 2001
 82-83 3 p. 273-284
12 p.
 artikel
268 Physico-chemical aspects of lactose for inhalation Kou, Xiang
 2012
 82-83 3 p. 220-232
13 p.
 artikel
269 Physico-chemical basis of specific interactions involving carbohydrates Petrak, Karel
 1994
 82-83 3 p. 211-213
3 p.
 artikel
270 Physiologically-based pharmacokinetic simulation modelling Grass, George M
 2002
 82-83 3 p. 433-451
19 p.
 artikel
271 PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines Waeckerle-Men, Ying
 2005
 82-83 3 p. 475-482
8 p.
 artikel
272 PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect Acharya, Sarbari
 2011
 82-83 3 p. 170-183
14 p.
 artikel
273 Polyionic drug-sensitive membrane electrodes: principles and practice Fu, Bin
 1996
 82-83 3 p. 215-223
9 p.
 artikel
274 Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines O'Hagan, Derek T
 1998
 82-83 3 p. 225-246
22 p.
 artikel
275 Polymeric controlled drug delivery Leong, K.W.
 1988
 82-83 3 p. 199-233
35 p.
 artikel
276 Polymorphism in generic drug product development Snider, Daniel A.
 2004
 82-83 3 p. 391-395
5 p.
 artikel
277 Potential and problems of developing transdermal patches for veterinary applications Riviere, Jim E
 2001
 82-83 3 p. 175-203
29 p.
 artikel
278 Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect Matsumura, Yasuhiro
 2011
 82-83 3 p. 184-192
9 p.
 artikel
279 Prediction of ‘drug-likeness’ Walters, W.Patrick
 2002
 82-83 3 p. 255-271
17 p.
 artikel
280 Prediction of drug solubility from structure Jorgensen, William L.
 2002
 82-83 3 p. 355-366
12 p.
 artikel
281 Prediction of intestinal permeability Egan, William J.
 2002
 82-83 3 p. 273-289
17 p.
 artikel
282 Preface 2013
 82-83 3 p. v-
1 p.
 artikel
283 Preface Kresina, Thomas F.
 1995
 82-83 3 p. 207-208
2 p.
 artikel
284 Preface Rathbone, Michael J
 1997
 82-83 3 p. 301-302
2 p.
 artikel
285 Preface Gulati, Anil
 2000
 82-83 3 p. 129-130
2 p.
 artikel
286 Preface Newman, Mark J
 1998
 82-83 3 p. 153-154
2 p.
 artikel
287 Preface Shen, Wei-Chiang
 1998
 82-83 3 p. 195-196
2 p.
 artikel
288 Preface Meadows, David L.
 1996
 82-83 3 p. 177-
1 p.
 artikel
289 Preface Korting, Hans C.
 1996
 82-83 3 p. 271-272
2 p.
 artikel
290 Preface Crison, John R
 2000
 82-83 3 p. 163-164
2 p.
 artikel
291 Preface Marriott, C.
 1993
 82-83 3 p. vii-
1 p.
 artikel
292 Preface Juliano, R.L.
 1991
 82-83 3 p. v-vi
nvt p.
 artikel
293 Preface Lee, Vincent H.L.
 1991
 82-83 3 p. v-
1 p.
 artikel
294 Preface Morgan, Jeffrey R.
 1993
 82-83 3 p. vii-viii
nvt p.
 artikel
295 Preface Crommelin, D.J.A.
 1990
 82-83 3 p. v-
1 p.
 artikel
296 Preface Tomlinson, Eric
 1990
 82-83 3 p. v-
1 p.
 artikel
297 Preface Poste, George
 1988
 82-83 3 p. iii-iv
nvt p.
 artikel
298 Preface Juliano, R.L.
 1989
 82-83 3 p. iii-
1 p.
 artikel
299 Pre-mRNA splicing as a target for antisense oligonucleotides Kole, Ryszard
 1991
 82-83 3 p. 271-286
16 p.
 artikel
300 Preparation and purification of antibody-enzyme conjugates for therapeutic applications Melton, Roger G
 1996
 82-83 3 p. 289-301
13 p.
 artikel
301 Progress in understanding the structure–activity relationships of P-glycoprotein Stouch, Terry R
 2002
 82-83 3 p. 315-328
14 p.
 artikel
302 Protein release from alginate matrices Gombotz, Wayne R
 1998
 82-83 3 p. 267-285
19 p.
 artikel
303 Protein release from collagen matrices Fujioka, Keiji
 1998
 82-83 3 p. 247-266
20 p.
 artikel
304 Protein release from gelatin matrices Tabata, Yasuhiko
 1998
 82-83 3 p. 287-301
15 p.
 artikel
305 Protein release from polyphosphazene matrices Andrianov, Alexander K
 1998
 82-83 3 p. 185-196
12 p.
 artikel
306 Pulmonary delivery of drugs for bone disorders Patton, John S
 2000
 82-83 3 p. 239-248
10 p.
 artikel
307 Purification and chemical modifications of hemoglobin in developing hemoglobin based oxygen carriers Haney, Chad R.
 2000
 82-83 3 p. 153-169
17 p.
 artikel
308 Quantitative studies on the nuclear transport of plasmid DNA and gene expression employing nonviral vectors Tachibana, Rieko
 2001
 82-83 3 p. 219-226
8 p.
 artikel
309 Recent advances in bovine reproductive endocrinology and physiology and their impact on drug delivery system design for the control of the estrous cycle in cattle Rathbone, Michael J.
 2001
 82-83 3 p. 277-320
44 p.
 artikel
310 Recent developments with biosensing technology and applications in the pharmaceutical industry Meadows, David
 1996
 82-83 3 p. 179-189
11 p.
 artikel
311 Receptor-mediated delivery of foreign genes to hepatocytes Wu, George Y
 1998
 82-83 3 p. 243-248
6 p.
 artikel
312 Receptor-mediated targeted drug or toxin delivery Řı́hová, Blanka
 1998
 82-83 3 p. 273-289
17 p.
 artikel
313 Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs) Raw, Andre S
 2004
 82-83 3 p. 397-414
18 p.
 artikel
314 Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injury Scott, Neal A.
 2006
 82-83 3 p. 358-376
19 p.
 artikel
315 Ribozyme gene therapy for HIV infection Intracellular immunization of lymphocytes and CD34+ cells with an anti-HIV-1 ribozyme gene Wong-Staal, Flossie
 1995
 82-83 3 p. 363-368
6 p.
 artikel
316 Role of dosage regimen in controlling indirect pharmacodynamic responses Gobburu, Jogarao V.S.
 1998
 82-83 3 p. 221-233
13 p.
 artikel
317 Role of stent design and coatings on restenosis and thrombosis Hara, Hidehiko
 2006
 82-83 3 p. 377-386
10 p.
 artikel
318 Role of the N-terminal peptides of viral envelope proteins in membrane fusion Martin, Isabelle
 1999
 82-83 3 p. 233-255
23 p.
 artikel
319 Roles of exosomes and microvesicles in disease pathogenesis Ohno, Shin-ichiro
 2013
 82-83 3 p. 398-401
4 p.
 artikel
320 Rumen-stable delivery systems Wu, Stephen H.W
 1997
 82-83 3 p. 323-334
12 p.
 artikel
321 Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates Senter, Peter D
 2001
 82-83 3 p. 247-264
18 p.
 artikel
322 Sensor methods for use with microdialysis and ultrafiltration Ballerstadt, Ralph
 1996
 82-83 3 p. 225-238
14 p.
 artikel
323 Separation processes for organic molecules using SCF Technologies Daintree, L.S.
 2008
 82-83 3 p. 351-372
22 p.
 artikel
324 Show me the pathway! Turner, Jerrold R
 2000
 82-83 3 p. 265-281
17 p.
 artikel
325 Site specific microencapsulated drug targeting strategies- liver and gastro-intestinal tract targeting D'Souza, Martin J.
 1995
 82-83 3 p. 247-254
8 p.
 artikel
326 Site-specific modifications and toxicity of blood substitutes D’Agnillo, Felice
 2000
 82-83 3 p. 199-212
14 p.
 artikel
327 Site-specific protein glycosylation Parekh, R.B.
 1994
 82-83 3 p. 251-266
16 p.
 artikel
328 Some biological issues in oral, controlled drug delivery Gruber, Peter
 1988
 82-83 3 p. 268-
1 p.
 artikel
329 Structure-stability relationships in proteins: a guide to approaches to stabilizing enzymes Mozhaev, Vadim V.
 1990
 82-83 3 p. 387-419
33 p.
 artikel
330 Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation Moribe, Kunikazu
 2008
 82-83 3 p. 328-338
11 p.
 artikel
331 Supercritical fluid technologies: An innovative approach for manipulating the solid-state of pharmaceuticals Pasquali, Irene
 2008
 82-83 3 p. 399-410
12 p.
 artikel
332 Sustained release emphasizing recombinant human bone morphogenetic protein-2 Winn, Shelley R
 1998
 82-83 3 p. 303-318
16 p.
 artikel
333 Synthesis of glycosphingolipids and corresponding neoglycolipids Magnusson, Göran
 1994
 82-83 3 p. 267-284
18 p.
 artikel
334 Targeted delivery to the pilosebaceous unit via liposomes Lauer, Andrea C.
 1996
 82-83 3 p. 311-324
14 p.
 artikel
335 Targeted delivery using inorganic nanosystem Mukherjee, Priyabrata
 2010
 82-83 3 p. 283-
1 p.
 artikel
336 Targeted hyperthermia using metal nanoparticles Cherukuri, Paul
 2010
 82-83 3 p. 339-345
7 p.
 artikel
337 Targeted therapy for viral hepatitis Plourde, Robert
 1995
 82-83 3 p. 311-315
5 p.
 artikel
338 Targeting immune response induction with cochleate and liposome-based vaccines Gould-Fogerite, Susan
 1998
 82-83 3 p. 273-287
15 p.
 artikel
339 Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery Bromberg, Lev E
 1998
 82-83 3 p. 197-221
25 p.
 artikel
340 The biochemical and physiological characteristics of receptors Feener, Edward P
 1998
 82-83 3 p. 197-213
17 p.
 artikel
341 The computational prediction of pharmaceutical crystal structures and polymorphism Price, Sarah L
 2004
 82-83 3 p. 301-319
19 p.
 artikel
342 The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors Needham, David
 2001
 82-83 3 p. 285-305
21 p.
 artikel
343 The effect of gastro-intestinal mucus on drug absorption MacAdam, Angela
 1993
 82-83 3 p. 201-220
20 p.
 artikel
344 The effects of electric current applied to skin: A review for transdermal drug delivery Prausnitz, Mark R.
 1996
 82-83 3 p. 395-425
31 p.
 artikel
345 The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Fang, Jun
 2011
 82-83 3 p. 136-151
16 p.
 artikel
346 The immunogenicity of CpG-antigen conjugates Wagner, Hermann
 2009
 82-83 3 p. 243-247
5 p.
 artikel
347 The molecular structure of the tight junction Lapierre, Lynne A
 2000
 82-83 3 p. 255-264
10 p.
 artikel
348 The nature of the epidermal barrier: biochemical aspects Wertz, Philip W.
 1996
 82-83 3 p. 283-294
12 p.
 artikel
349 The nature of the epidermal barrier: structural aspects Fartasch, Manigé
 1996
 82-83 3 p. 273-282
10 p.
 artikel
350 Theory and practice of site-specific drug delivery Tomlinson, E.
 1988
 82-83 3 p. 271-272
2 p.
 artikel
351 Therapeutic progress with topical liposome drugs for skin disease Schmid, M.-H.
 1996
 82-83 3 p. 335-342
8 p.
 artikel
352 Therapeutic uses of agonistic monoclonal antibodies to human lymphocyte cell-surface molecules Ledbetter, Jeffrey A.
 1988
 82-83 3 p. 319-342
24 p.
 artikel
353 The relevance of nasal physiology to the design of drug absorption studies Gizurarson, Sveinbjörn
 1993
 82-83 3 p. 329-347
19 p.
 artikel
354 Thermosensitive polymer-modified liposomes Kono, Kenji
 2001
 82-83 3 p. 307-319
13 p.
 artikel
355 The role of anti-I-A antibody therapy in the management of autoimmune disease and in transplantation Fox, Ira J.
 1988
 82-83 3 p. 359-367
9 p.
 artikel
356 The role of caveolae and caveolin in vesicle-dependent and vesicle-independent trafficking Matveev, Sergey
 2001
 82-83 3 p. 237-250
14 p.
 artikel
357 The role of exosomes and microRNAs in senescence and aging Xu, Dan
 2013
 82-83 3 p. 368-375
8 p.
 artikel
358 The role of liposomal delivery in cutaneous DNA repair Yarosh, Daniel
 1996
 82-83 3 p. 325-333
9 p.
 artikel
359 The role of percutaneous penetration enhancers Walker, Roderick B.
 1996
 82-83 3 p. 295-301
7 p.
 artikel
360 The role of tracheobronchial mucus in drug administration to the airways Lethem, Michael I.
 1993
 82-83 3 p. 271-298
28 p.
 artikel
361 The skin: a pathway for systemic treatment with patches and lipid-based agent carriers Cevc, Gregor
 1996
 82-83 3 p. 349-378
30 p.
 artikel
362 The Taxus™ drug-eluting stent: A new paradigm in controlled drug delivery Kamath, Kalpana R.
 2006
 82-83 3 p. 412-436
25 p.
 artikel
363 The use of bioadhesives in targeted delivery within the gastrointestinal tract Helliwell, Mark
 1993
 82-83 3 p. 221-251
31 p.
 artikel
364 The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system Allen, T.M.
 1994
 82-83 3 p. 285-309
25 p.
 artikel
365 The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers Jones, Matthew D.
 2012
 82-83 3 p. 285-293
9 p.
 artikel
366 The use of liposomes in the therapy of liver disease Yao, Tony
 1995
 82-83 3 p. 239-246
8 p.
 artikel
367 Tissue perfusion and oxygenation with blood substitutes Habler, Oliver P.
 2000
 82-83 3 p. 171-184
14 p.
 artikel
368 Tissue-specific targeting of retroviral vectors via ligand-receptor interactions Kasahara, Noriyuki
 1995
 82-83 3 p. 227-234
8 p.
 artikel
369 To fuse or not to fuse: the effects of electrostatic interactions, hydrophobic forces, and structural amphiphilicity on protein-mediated membrane destabilization Fujii, Gary
 1999
 82-83 3 p. 257-277
21 p.
 artikel
370 Towards synthetic viruses Zuber, Guy
 2001
 82-83 3 p. 245-253
9 p.
 artikel
371 Transdermal delivery of drugs for the treatment of bone diseases Ramachandran, Chandrasekharan
 2000
 82-83 3 p. 197-223
27 p.
 artikel
372 Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption Yu, Lawrence X.
 1996
 82-83 3 p. 359-376
18 p.
 artikel
373 Treatment of diseases of the eye with mucoadhesive delivery systems Greaves, Jane L.
 1993
 82-83 3 p. 349-383
35 p.
 artikel
374 Trends in particulate antigen and DNA delivery systems for vaccines Gander, Bruno
 2005
 82-83 3 p. 321-323
3 p.
 artikel
375 Triggering in drug delivery systems 2001
 82-83 3 p. 245-
1 p.
 artikel
376 Tumor delivery of macromolecular drugs based on the EPR effect Torchilin, Vladimir
 2011
 82-83 3 p. 131-135
5 p.
 artikel
377 Two future generations of blood substitutes based on polyhemoglobin–SOD–catalase and nanoencapsulation Chang, T.M.S.
 2000
 82-83 3 p. 213-218
6 p.
 artikel
378 Upregulation of caveolin in multidrug resistant cancer cells: functional implications Lavie, Yaakov
 2001
 82-83 3 p. 317-323
7 p.
 artikel
379 Use of CpG oligonucleotides in treatment of asthma and allergic disease Fonseca, David E.
 2009
 82-83 3 p. 256-262
7 p.
 artikel
380 VDEPT: An enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer Huber, Brian E.
 1995
 82-83 3 p. 279-292
14 p.
 artikel
381 Veterinary drug delivery – Part IV 2001
 82-83 3 p. 173-174
2 p.
 artikel
382 Veterinary drug delivery: potential for skin penetration enhancement Magnusson, Beatrice M
 2001
 82-83 3 p. 205-227
23 p.
 artikel
383 Virosomes for antigen and DNA delivery Daemen, Toos
 2005
 82-83 3 p. 451-463
13 p.
 artikel
384 Virus-modified exosomes for targeted RNA delivery; A new approach in nanomedicine Koppers-Lalic, Danijela
 2013
 82-83 3 p. 348-356
9 p.
 artikel
385 Zotarolimus (ABT-578) eluting stents Burke, Sandra E.
 2006
 82-83 3 p. 437-446
10 p.
 artikel
                             385 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland